Imunon Q2 2026: $6.9M Cash, Going Concern Warning, and $10M Financing Closed
IMNN sits 16% above its 52-week low of $1.47 on light trading volume (0.3× avg).
Summary
Imunon reports $6.9M in cash, a $7.1M H1 net loss, and a going concern warning. A $10M financing closed in June, but $5M is restricted, and the ATM program continues to dilute shareholders.
Key Events · Earnings and Guidance · IMNN
-
Going Concern Warning Reiterated
Management states substantial doubt about the company's ability to continue as a going concern, with current capital insufficient to fund operations for the next twelve months.
-
Cash Position and Burn
Unrestricted cash of $6.9 million at June 30, 2026, after burning $7.0 million in H1 2026. $5.0 million of the $10 million June financing is restricted as collateral.
-
June 2026 Financing Closed
Closed a $10 million transaction with Streeterville Capital on June 3, 2026, consisting of $2.5 million in Series A preferred stock, a $2.72 million A-1 note, and a $5.0 million B note. $5 million of proceeds are restricted.
-
ATM Dilution Continues
Sold 356,976 shares for net proceeds of $842,702 in H1 2026. Post-quarter, sold another 162,804 shares for $298,494. The ATM program has $12.2 million remaining capacity.
Analysis · IMNN · Life Sciences
With only $6.9 million in unrestricted cash after burning $7.0 million in the first half, Imunon ended Q2 2026 on a precarious footing. Management reiterates substantial doubt about the company's ability to continue as a going concern, stating current capital is insufficient to fund operations for the next twelve months. A $10 million financing closed in June — a mix of preferred stock and secured notes — provides a lifeline, but $5 million of the proceeds is restricted as collateral, leaving just $5 million immediately available. The company continues to sell shares through its ATM program, raising an additional $298,494 after the quarter. While clinical progress with IMNN-001 in ovarian cancer is encouraging, the financial runway remains critically short, and further dilution is virtually certain.
At the time of this filing, IMNN was trading at $1.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $1.47 to $7.28. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.